Cost analysis of the combined procedure of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC)

Abstract 

Aim

The aim of the present study was to address the economic cost of the innovative comprehensive approach involving cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) to treat peritoneal surface malignancies, and to compare it with the financial support received by our centre.

Methods

A retrospective economic analysis was carried out on 382 consecutive procedures performed at a tertiary referral centre during the period 1995–2008. The costs of the combined therapy were estimated using the activity-based costing methodology. The financial support was assessed according to the current diagnosis-related group classification and reimbursement rates.

Results

The mean cost for one hospital stay was €36,015.89 (range 28,435.24–82,189.08); mean length of stay was 24.3 days (range 9–108). In counterpart, our hospital received a total financial support of €804,483.30, resulting in a deficit of €1861,301.99 for the two years.

Conclusion

The Italian current diagnosis-related groups classification does not include cytoreduction and HIPEC. This results in a relevant economic deficit for the hospitals offering this treatment option to their patients and a slow diffusion of the technique in our country. Two corrective measures are needed: to include this procedure in the official list of medical acts, and to determine its specific cost for reimbursing.

Keywords: Peritoneal surface malignancies, Cytoreductive surgery, Hyperthermic intraperitoneal chemotherapy, Costs, Diagnosis related group, HIPEC